News and Announcements
Latest coverage from Edison Research on Kazia’s recent initial efficacy data from its phase II trial of GDC-0084 in glioblastoma
- Published November 27, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
We’re pleased to provide the latest coverage from Edison Research on Kazia’s recent initial efficacy data from its phase II trial of GDC-0084 in glioblastoma.
The report states that the data is “very encouraging” and that it is “sufficient to give Kazia confidence that it can run a large, and potentially pivotal, study starting by mid-CY20.”
Edison also states that it assumes that this single pivotal trial might be adequate for FDA approval of GDC-0084 in 2024 “as patients resistant to the current standard therapy, temozolomide, have no other options available.”
Edison has a valuation on Kazia of A$137 million.
You can read the full research report, which includes a video interview with CEO, Dr James Garner, on GDC-0084 here
About KaziaTherapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
